|View printer-friendly version|
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
The presentation at the ASH Annual Meeting will highlight new preclinical data supporting Cidara’s rezafungin program for the prevention of invasive fungal infections. The presentation at the Interdisciplinary Meeting on Anti-Infective Chemotherapy will provide an overview of Cidara’s rezafungin clinical development program for the treatment and prevention of invasive fungal infections.
Poster Presentation at the 61st ASH Annual Meeting
Title: Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis Reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II
Date and Time:
Oral Presentation at the 39th Interdisciplinary Meeting on Anti-Infective Chemotherapy
Title: Antifungals, What’s New in 2019?
Date and Time:
Location: Palais des Congrès de
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). Cidara is also advancing a second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) initially in
Karen O’Shea, Ph.D.
LifeSci Public Relations
Source: Cidara Therapeutics, Inc.